Speakers

Expand/Collapse

Hans-Peter Gerber
CEO & CSO
3T Biosciences

Day One

Wednesday, April 14th 2021

8:45 am | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Focus Day

1:50 pm | Audience discussion

12:10 pm | Designing Best in Class TCR Cell Therapies Against Novel Antigens

Melanie Patterson
Principal Research Scientist II
Abbvie

Maren Lang
Head of Bioinformatics Research & Development
BioNTech SE

Jens Kringelum
Director, Genomic Immuno-Oncology
Exaxion Biotech

Wigard Kloosterman
CSO
Frame Cancer Therapeutics

Day One

Wednesday, April 14th 2021

4:45 pm | Whole Framome Cancer vaccination

Hubert Lam
Director, Pre-clinical Development
Genocea

Day Two

Thursday, April 15th 2021

9:30 am | The Impact of Stimulatory and Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical and Pre- Clinical Results

Pranay Khare
Director, Cell Therapy Development & Manufacturing
Genocea Biosciences

Jennie Lill
Senior Director of Proteomics & NGS
Genentech

Focus Day

11:40 am | Engineered T cells for the Treatment of Malignancy

Raymond Miller
Senior Global Product Manager, Therapeutic Materials
GenScript Biotech Corporation

Andrew Allen
CEO
Gritstone

Day One

Wednesday, April 14th 2021

9:15 am | Personalised Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step

8:45 am | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Gerben Zondag
CEO
Immunetune

Sijme Zeilemaker
COO
Immunicum

Lei Zheng
Associate Professor
John Hopkins School of Medicine

Alexandre Harari
Group leader, Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

John Johnston
Clinical Assessor
MHRA

Day Two

Thursday, April 15th 2021

10:00 am | What Does Brexit Mean for Production of Neoantigen Therapies?

Wim Van Criekinge
CSO
myNeo

Day Two

Thursday, April 15th 2021

3:30 pm | Extrapolation of epitope prediction from IO onto infectious diseases (lessons learned)

Elisa Scarselli
CSO and Co-founder
Nouscom

Day Two

Thursday, April 15th 2021

3:00 pm | Panel Discussion: Evaluating Combination Therapies

2:30 pm | Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression

Pia Kvistborg
Junior group leader, Department of Immunology
The Netherlands Cancer Institute

Focus Day

10:40 am | Delving into the Properties of T-Cell Recognized Neoantigens

Trevor Clancy
CSO & Co-founder
OncoImmunity

Day One

Wednesday, April 14th 2021

9:45 am | An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

Sean Boyle
Senior Director, Bioinformatics Applications
Personalis

Day One

Wednesday, April 14th 2021

4:15 pm | ImmunoID NeXT: A Comprehensive Platform for Improving Neoantigen Prediction, Tumour Escape Mechanism Reporting, TME Assessment, & Tumor Heterogeneity Profiling for Immuno-Oncology

Philip Arlen
CEO & CMO
Precision Biologics

Kaidre Bendjama
Project Leader, Personalized Cancer Vaccines
Transgene

Day Two

Thursday, April 15th 2021

1:00 pm | TG4050 : Viral immunotherapy meets AI technology

Nicola Ternette
Head of Immunopeptidomics
University of Oxford

Russell Pachynski
Assistant Professor, Division of Oncology
Washington University School of Medicine

Sara Mangsbo
Associate Professor
Uppsala University Sweden

Agnete Fredriksen
President & Chief Scientific Officer
Vaccibody

Day Two

Thursday, April 15th 2021

3:00 pm | Panel Discussion: Evaluating Combination Therapies

9:00 am | The Importance of Different Vaccine Platforms, Neoepitope Selection & Clinical Trial design to Show Vaccine-induced Clinical Efficacy

Alena Gros
Principal Investigator, Tumor Immunology & Immunotherapy
Vall d’Hebron Institute of Oncology (V.H.I.O)

Focus Day

10:10 am | Novel Strategies to Improve Personalized Neoantigen Discovery

Sari Pesonen
Head of R&D
Valo Therapeutics

Heinz Lubenau
Chief Operating Officer & Co-Founder
Vaximm

Day Two

Thursday, April 15th 2021

3:00 pm | Panel Discussion: Evaluating Combination Therapies

Kostas Kosmatopoulos
CEO
Vaxon Biotech

Eniko R Toke
Chief Scientific Officer
Treos Bio

Day One

Wednesday, April 14th 2021

5:15 pm | A Personal Antigen Selection Calculator (PASCal) for the Design of Off-The-Shelf, Shared Neoantigen-Based Personal Vaccines